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INTRODUCTION. Parkinson’s disease is the second most important neurodegenerative disease affecting 1% of the population over 60 years old. PD
hallmarks are dopaminergic neurons loss and the presence of fibrillar α-synuclein, known as Lewy’s bodies (LB), on surviving cells. Previous studies
has revealed that histone H1 interacts with α-synuclein accelerating its fibrillation. It has been seen as well that in neurodegenerating conditions
histone H1 overexpression does not change while its localization does, senile plaques present in brains with Alzheimer’s disease are
immunoreactive for histone H1. What is more nuclear localization of histone H1 causes neurotoxicity but on the other hand its sequestration on
the cytosol is neuroprotective. All those points make us realize that histone H1 must have an important role not just in PD but also in other
neurodegenerative diseases.
CHARACTERIZATION OF α-SYNUCLEIN AND HISTONE H1 INTERACTION AND ITS 
POTENTIAL ROLE AS THERAPEUTIC TARGET IN TREATMENT OF PARKINSON’S DISEASE
OBJECTIVES 
To study the role of histone H1 phosphorylation,
methylation and acetylation in the α-synuclein
fibrillation rate.
To study the nature of the interaction between the
two proteins.
To determine if fibrillar α-synuclein is more sensitive
to proteolysis than the complex α-synuclein/histone-
H1
METHODOLOGY
We will perform qualitative and quantitative assays in order to obtain brand new
information about the role of histone H1 in PD due its interaction with α-
synuclein. How?
•In vitro assays using human α-synuclein expressed in Escherichia coli.
•In vivo assays using α-synuclein purified from an animal model.
•α-synuclein- histone H1 complex formation in vitro will be tested using ThT
fluorescence, FTIR spectroscopy and native PAGE.
•The nature of the interaction between the two proteins will be assayed in vivo
changing medium composition and its effect will be tested by electron
microscopy, ThT fluorescence and native PAGE.
•In vitro proteolithic assay is going to be done using kallikrein-6 and the result will
be assayed by electron microscopy and FTIR spectroscopy
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• Histone H1 and histone H1 with posttranslational modifications
are expected to increase α-synuclein aggregation rate, been the
effect higher in phosphorylated histone H1.
• α-synuclein-histone H1 complex should be less sensitive to
proteolysis due fibrill α-synuclein stabilization thanks to histone
H1 protective effect.
• Histone H1 and α-synuclein has opposite net charge it is
believed that their interaction is electrostatic so salty medium
will affect complex formation.
• Considering the role of histone H1 in many neurodegenerative
disease we believe that characterizing α-synuclein and histone
H1 interaction could lead to the development of brand new
therapies that will reduce dopaminergic neuronal loss.
Figure 1: FTIR spectroscopy
FTIR is used to study secondary 
structure. It’s possible to distinguish 
between two regions of the 
spectra: a band around 1626 cm-1
(corresponding to ordered 
structures) and a band at 1645 cm-1 
indicative of unordered and helical 
structures. The ratio of 
A1626/A1645 is used to monitor β 
structure formation
Figure 2:Native PAGE Histone H1 and α-synuclein has
opposite net charge, in a native
PAGE they will run in opposite
directions while its complex
(without net charge) will stay on
the middle of the gel. The study
of the bands from the gel will
help us to analyze complex
formation.
Native Page of human recombinant α-
synuclein with increasing concentrations of 
histone H1.(Goers et al., 2003)
Infrared spectra of Aβ. 1,2,3,4 and 5 
correspond to different times of 
oligomeritzation. (Benseny-Cases, 
Cócera, & Cladera, 2007)
Figure 4: ELECTRON MICROSCOPY
With this technique we will evaluate if the 
introduction of histones H1 on the fibrils 
induce any drastic morphologic change 
and also how the fibrils are affected by 
proteolysis. 
α-synuclein and aged α-synuclein were visualized using electron 
microscopy. Aged α-synuclein show fibril formation. (Duce et al., 
2006)
Figure 3: THIOFLAVIN T FLUORESCENCE
Thiflavin T (ThT) is a molecule that 
increase its fluorescence when it is 
localized on a fibrilar structure.
Mesuring ThT fluorescence we will
monitoraize α-synuclein 
fibrillation. 
ThT fluorescence measurements. Acceleration of 
α-synuclein fibrilation with increasing
concentrations of histone H1. (Goers et al., 2003)
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